Citadel Advisors
RPRX icon

Citadel Advisors’s Royalty Pharma RPRX Stock Holding History

Citadel Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
217,300
+167,800
+339% +$7.35M ﹤0.01% 3197
2025
Q4 		$1.91M Sell
49,500
-116,400
-70% -$4.44M ﹤0.01% 6008
2025
Q3 		$5.85M Sell
165,900
-106,300
-39% -$3.85M ﹤0.01% 4070
2025
Q2 		$9.81M Buy
272,200
+34,500
+15% +$1.14M ﹤0.01% 3048
2025
Q1 		$7.4M Buy
237,700
+133,600
+128% +$4.23M ﹤0.01% 3288
2024
Q4 		$2.66M Buy
104,100
+18,000
+21% +$477K ﹤0.01% 5056
2024
Q3 		$2.44M Sell
86,100
-39,800
-32% -$1.1M ﹤0.01% 5155
2024
Q2 		$3.32M Buy
125,900
+44,600
+55% +$1.24M ﹤0.01% 4400
2024
Q1 		$2.47M Buy
81,300
+29,300
+56% +$864K ﹤0.01% 5111
2023
Q4 		$1.46M Sell
52,000
-17,800
-26% -$489K ﹤0.01% 5942
2023
Q3 		$1.89M Buy
69,800
+7,100
+11% +$211K ﹤0.01% 5318
2023
Q2 		$1.93M Sell
62,700
-19,600
-24% -$664K ﹤0.01% 5210
2023
Q1 		$2.97M Buy
82,300
+22,100
+37% +$819K ﹤0.01% 4650
2022
Q4 		$2.38M Sell
60,200
-136,000
-69% -$5.68M ﹤0.01% 5147
2022
Q3 		$7.88M Sell
196,200
-54,900
-22% -$2.34M ﹤0.01% 3111
2022
Q2 		$10.6M Buy
251,100
+149,800
+148% +$6.14M ﹤0.01% 2617
2022
Q1 		$3.95M Buy
101,300
+6,300
+7% +$247K ﹤0.01% 4639
2021
Q4 		$3.79M Sell
95,000
-21,100
-18% -$820K ﹤0.01% 4864
2021
Q3 		$4.2M Sell
116,100
-17,100
-13% -$665K ﹤0.01% 4641
2021
Q2 		$5.46M Buy
133,200
+49,500
+59% +$2.11M ﹤0.01% 4245
2021
Q1 		$3.65M Buy
83,700
+12,100
+17% +$574K ﹤0.01% 4987
2020
Q4 		$3.58M Buy
71,600
+46,900
+190% +$1.99M ﹤0.01% 4276
2020
Q3 		$1.04M Buy
24,700
+6,400
+35% +$275K ﹤0.01% 5961
2020
Q2 		$888K Buy
+18,300
New +$906K ﹤0.01% 6049

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's RPRX Position: Q1 2026 in Review

Citadel Advisors reduced its Royalty Pharma (RPRX) stake by 49% in Q1 2026, selling an estimated $114M and leaving 2,681,069 shares worth $129M. The position accounts for 0.02% of the portfolio, ranked #661.

Citadel Advisors first reported a position in RPRX in Q2 2020 and has held it in 22 quarters since. The position peaked at $204M in Q4 2025. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Citadel Advisors held 2,681,069 shares of Royalty Pharma worth $129M as of Q1 2026.
  • Citadel Advisors sold 2,592,796 Royalty Pharma shares in Q1 2026, an estimated $114M.
  • Royalty Pharma made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #661 holding.
  • Citadel Advisors first reported a position in Royalty Pharma in Q2 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Royalty Pharma position peaked at $204M in Q4 2025.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.